First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer

doi:10.3748/wjg.v19.i28.4511

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 28

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6332)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

388

HTML

3546

Figures (1-3)

174

Tables (1-4)

137

Sum=4245

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1144

Download

943

Sum=2087

Jul 28, 2013 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Jul 28, 2013; 19(28): 4511-4519
Published online Jul 28, 2013. doi: 10.3748/wjg.v19.i28.4511

Table 4 Multivariate analysis for progression-free survival and overall survival

Variables	PFS		OS
Variables	HR (95%CI)	P value	HR (95%CI)	P value
PS	NA		8.78 (1.60-48.2)	0.01
Gender	2.99 (1.13-7.90)	0.03	2.66 (0.85-8.35)	0.09
CB	NA		3.07 (0.87-10.8)	0.08
Skin rash¹	8.66 (2.65-28.32)	< 0.0001	5.10 (1.41-18.4)	0.01
CA 19-9 decrease²	2.64 (0.93-7.45)	0.07	3.36 (1.05-10.6)	0.04

¹None vs any grade;

²Carbohydrate antigen 19-9 (CA 19-9) decrease of ≥25%. PFS: Progression-free survival; OS: Overall survival; PS: Performance status according to Eastern Cooperative Oncology Group (PS 0-1 vs PS 2-3); CB: Clinical benefit; NA: Not applicable.

Citation: Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519
URL: https://www.wjgnet.com/1007-9327/full/v19/i28/4511.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i28.4511